Pre-emptive intravenous ganciclovir versus valganciclovir prophylaxis for de novo cytomegalovirus-seropositive kidney-transplant recipients

Transplant International

Volumn 23, Issue 10, 2010, Pages 1056-1064

  Weclawiak, Hugo ^a   Kamar, Nassim ^a   Mengelle, Catherine ^b   Esposito, Laure ^a   Mohamed, Abdellatif Ould ^a   Lavayssiere, Laurence ^a   Ribes, David ^a   Cointault, Olivier ^a   Nogier, Marie Béatrice ^a   Cardeau Desangles, Isabelle ^a   Izopet, Jacques ^b   Rostaing, Lionel ^a,b  

^a CHU RANGUEIL   (France)

^b CHU PURPAN   (France)

Author keywords

cytomegalovirus; glomerular filtration rate; kidney transplant; neutropenia; prophylaxis; valganciclovir

Indexed keywords

ABATACEPT; BELATACEPT; CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS; FINGOLIMOD; GANCICLOVIR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; SOTRASTAURIN; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; VIRUS DNA;

ADULT; AGE; AGED; ANTIVIRAL RESISTANCE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DONOR; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENDER; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; GANCICLOVIR; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; VIRUS ACTIVATION;

EID: 77956316641     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2010.01101.x     Document Type: Article

References (31)

1. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004 66 : 329.
2. Sagedal S, Nordal KP, Hartmann A, et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002 2 : 850.
3. Toupance O, Bouedjoro-Camus MC, Carquin J, et al. Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses. Transpl Int 2000 13 : 413.
4. Opelz G, Döhler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004 4 : 928.
5. Humar A, Gillingham KJ, Payne WD, Dunn DL, Sutherland DE, Matas AJ. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation 1999 68 : 1879.
6. Helantera I, Koskinen P, Tornroth T, Loginov R, Gronhagen-Riska C, Lautenschlager I. The impact of cytomegalovirus infections and acute rejection episodes on the development of vascular changes in 6-month protocol biopsy specimens of cadaveric kidney allograft recipients. Transplantation 2003 75 : 1858.
7. Reischig T, Jindra P, Hes O, Bouda M, Kormunda S, Treska V. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Transplantation 2009 87 : 436.
8. Paya CV. Indirect effects of CMV in the solid organ transplant patient. Transpl Infect Dis 1999 1 (Suppl 1 8.
9. Sagedal S, Nordal KP, Hartmann A, et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000 70 : 1166.
10. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005 143 : 870.
11. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005 365 : 2105.
12. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008 8 : 975.
13. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004 4 : 611.
14. Mengelle C, Pasquier C, Rostaing L, et al. Quantitation of human cytomegalovirus in recipients of solid organ transplants by real-time quantitative PCR and pp65 antigenemia. J Med Virol 2003 69 : 225.
15. Ljungman P. Workshop on CMV disease definitions, clinical severity scores and new syndromes. Scand J Infect Dis Suppl 1995 99 : 87.
16. Kalil AC, Freifeld AG, Lyden ER, Stoner JA. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. PLoS One 2009 4 : e5512, Epub 2009 May 13.
17. Humar A. Reactivation of viruses in solid organ transplant patients receiving cytomegalovirus prophylaxis. Transplantation 2006 2 (Suppl S9.
18. Kanter J, Pallardo L, Gavela E, et al. Cytomegalovirus infection in renal transplant recipients: risk factors and outcome. Transplant Proc 2009 41 : 2156.
19. San Juan R, Aguado JM, Lumbreras C, et al. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin Infect Dis 2008 47 : 875.
20. Basic-Jukic N, Kes P, Bubic-Filipi LJ, Puretic Z, Brunetta B, Pasini J. Does mycophenolate mofetil increase the incidence of cytomegalovirus disease compared with azathioprine after cadaveric transplantation? Transplant Proc 2005 37 : 850.
21. Song AT, Abdala E, Bonazzi PR, Bacchella T, Machado MC. Does mycophenolate mofetil increase the risk of cytomegalovirus infection in solid organ transplant recipients? A mini-review after cadaveric transplantation? Braz J Infect Dis 2006 10 : 132.
22. Kamar N, Mengelle C, Esposito L, et al. Predictive factors for cytomegalovirus reactivation in cytomegalovirus-seropositive kidney-transplant patients. J Med Virol 2008 80 : 1012.
23. Akalin E, Sehgal V, Ames S, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003 3 : 731.
24. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006 6 : 2134.
25. Humar A, Lebranchu Y, Vincenti F, et al. The IMPACT study: Valganciclovir prophylaxis until 200 days post-transplant in high risk kidney recipients substantially reduces the incidence of CMV disease. Am J Transplant 2009 9 (Suppl 2 248.
26. Luan FL, Stuckey LJ, Park JM, Kaul D, Cibrik D, Ojo A. Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection. J Am Soc Nephrol 2009 20 : 2449.
27. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002 62 : 311.
28. Fritzsimmons WE, Thompson D, Hariharan S, Van Veldhuisen P. Serum creatinine as a surrogate endpoint for graft loss in kidney transplantation: validation efforts from multicenter trials. Am J Transplant 2002 2 (Suppl 3 272.
29. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999 340 : 1462.
30. Hjelmesaeth J, Sagedal S, Hartmann A, et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004 47 : 1550.
31. Walker JK, Scholz LM, Scheetz MH, et al. Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction. Transplantation 2007 83 : 874.